Does <i>de novo</i> malignancy heighten the risk of rejection in kidney transplant recipients?
In kidney transplant recipients with <i>de novo</i> malignancies, death with a functioning graft remains significant. However, allograft loss rates do not increase compared with those without malignancies, and rejection risk is reduced, especially in older and chemotherapy-treated patients. These findings suggest that managing immunosuppression reduction in this population may be appropriate, but further research is needed to determine optimal care strategies.
Authors
- Aslıhan Pekmezci (ORCID: https://orcid.org/0000-0002-8269-2607)
- Nurhan Seyahi (ORCID: https://orcid.org/0000-0001-7427-618X)
- Aydın Türkmen (ORCID: https://orcid.org/0000-0003-3664-8469)
- Cansu Erel (ORCID: https://orcid.org/0000-0001-8427-0881)
- Cebrail Karaca (ORCID: https://orcid.org/0000-0003-0969-7708)
- Sinan Trabulus (ORCID: https://orcid.org/0000-0003-3843-5950)
- Latif Karahan (ORCID: https://orcid.org/0000-0001-5238-0883)
- Mevlüt Tamer Dinçer (ORCID: https://orcid.org/0000-0002-5397-7697)
- Erol Demir (ORCID: https://orcid.org/0000-0003-0128-5645)
Institutions
- Koç University (TR)
- Istanbul University-Cerrahpaşa (TR)
- Istanbul University (TR)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1093/ckj/sfae349
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00